{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:03:59Z","timestamp":1779764639673,"version":"3.53.1"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases, affecting patients\u2019 quality of life, particularly when involving difficult-to-treat areas. While randomized controlled trials have shown that ixekizumab is effective for psoriatic disease, real-world evidence is essential for assessing its broader applicability. This retrospective, single-centre study evaluated the effectiveness and safety of ixekizumab in 37 Greek patients with psoriasis and\/or PsA, including involvement of difficult-to-treat areas, over 52 weeks of treatment. Ixekizumab led to significant and sustained improvements in skin disease up to week 52. Joint manifestations and difficult-to-treat sites showed marked improvement, as did patient-reported quality of life. Biologic-na\u00efve patients and those with early-onset disease showed better responses. No serious adverse events were reported, and cardiovascular parameters remained stable. These findings support ixekizumab\u2019s strong efficacy and safety in routine clinical use, including in patients with prior biologic exposure and complex disease, reinforcing its role as a cornerstone therapy.<\/jats:p>","DOI":"10.1093\/ced\/llag055","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:38:31Z","timestamp":1769863111000},"page":"1070-1075","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of ixekizumab from the joint psoriasis and psoriatic arthritis clinic"],"prefix":"10.1093","volume":"51","author":[{"given":"Aristeidis G","family":"Vaiopoulos","sequence":"first","affiliation":[{"name":"First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelagia","family":"Katsimbri","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Lazarou-Athanasopoulou","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charikleia","family":"Tzavara","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Theodoropoulos","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So\ufb01a","family":"Theotokoglou","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-7641","authenticated-orcid":false,"given":"Antonios","family":"Kanelleas","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Syrmali","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Lampadaki","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Katsifis-Nezis","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sabatakaki","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tseronis","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Zoupidou","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pavlidis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Katoulis","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"Second Department of Dermatology and Venereorology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026052522563733800_llag055-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026052522563733800_llag055-B2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2026052522563733800_llag055-B3","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"2026052522563733800_llag055-B4","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/jdv.14470","article-title":"Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris \u2013 Update apremilast and secukinumab \u2013 EDF in cooperation with EADV and IPC","volume":"31","author":"Dressler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026052522563733800_llag055-B5","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.14237","article-title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)","volume":"31","author":"Menter","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026052522563733800_llag055-B6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/acr2.11676","article-title":"Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States","volume":"6","author":"Rohekar","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"2026052522563733800_llag055-B7","doi-asserted-by":"crossref","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","article-title":"Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study","volume":"15","author":"Ntawuyamara","year":"2025","journal-title":"Sci Rep"},{"key":"2026052522563733800_llag055-B8","doi-asserted-by":"crossref","first-page":"e13283","DOI":"10.1111\/dth.13283","article-title":"How does the joint dermatology\u2013rheumatology clinic benefit both\u00a0patients and dermatologists?","volume":"33","author":"Theodorakopoulou","year":"2020","journal-title":"Dermatol Ther"},{"key":"2026052522563733800_llag055-B9","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification Criteria for Psoriatic Arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026052522563733800_llag055-B10","first-page":"100","article-title":"Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026052522563733800_llag055-B11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/ph15020172","article-title":"Apremilast improves endothelial glycocalyx integrity, vascular and left ventricular myocardial function in psoriasis","volume":"15","author":"Ikonomidis","year":"2022","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag055\/66731359\/llag055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1070\/66731359\/llag055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1070\/66731359\/llag055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:56:43Z","timestamp":1779764203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/1070\/8456593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":11,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag055","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,3]]}}}